BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16197621)

  • 1. Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program.
    Atkins JN; Jacobs SA; Wieand HS; Smith RE; John WJ; Colangelo LH; Vogel VG; Kuebler JP; Cescon TP; Miller BJ; Geyer CE; Wolmark N
    Clin Colorectal Cancer; 2005 Sep; 5(3):181-7. PubMed ID: 16197621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed in advanced colorectal cancer.
    Louvet C; de Gramont A
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.
    Alberts SR; Kim GP; Mahoney MR; Gornet MK; Rubin J; Ames M; Goetz MP; Weinshilboum RM; Nicol SJ; Goldberg RM
    Clin Colorectal Cancer; 2007 Jul; 6(8):572-7. PubMed ID: 17681103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Wu XY; Huang XE; You SX; Lu YY; Cao J; Liu J
    Asian Pac J Cancer Prev; 2013; 14(3):2019-22. PubMed ID: 23679311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.
    Celio L; Sternberg CN; Labianca R; La Torre I; Amoroso V; Barone C; Pinotti G; Cascinu S; Di Costanzo F; Cetto GL; Bajetta E
    Ann Oncol; 2009 Jun; 20(6):1062-7. PubMed ID: 19218305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.
    Hochster H; Kettner E; Kroning H; Becker K; Lordick F; Ramanathan RK; Macdonald J; Hong S; John W; Schmoll HJ
    Clin Colorectal Cancer; 2005 Nov; 5(4):257-62. PubMed ID: 16356302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
    Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
    Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
    Scagliotti GV; Kortsik C; Dark GG; Price A; Manegold C; Rosell R; O'Brien M; Peterson PM; Castellano D; Selvaggi G; Novello S; Blatter J; Kayitalire L; Crino L; Paz-Ares L
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):690-6. PubMed ID: 15701857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of Loubo® (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes.
    Deng QQ; Huang XE; Ye LH; Lu YY; Liang Y; Xiang J
    Asian Pac J Cancer Prev; 2013; 14(1):413-7. PubMed ID: 23534764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
    Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
    Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
    Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
    Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
    Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
    Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
    Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
    Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.
    Ma CX; Steen P; Rowland KM; Niedringhaus RD; Fitch TR; Kugler JW; Hillman DW; Perez EA; Ingle JN; Adjei AA
    Ann Oncol; 2006 Feb; 17(2):226-31. PubMed ID: 16303865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
    Scheithauer W; Kornek GV; Ulrich-Pur H; Penz M; Raderer M; Salek T; Haider K; Kwasny W; Depisch D
    Cancer; 2001 Apr; 91(7):1264-71. PubMed ID: 11283925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.